Pancreatic Ca Update
|
|
- Colin McDowell
- 5 years ago
- Views:
Transcription
1 Pancreatic Ca Update Caio Max S. Rocha Lima, M.D. M. Robert Cooper Professor in Medical Oncology Co-leader GI Oncology and Co-leader Phase I Program Wake Forest School of Medicine crochali@wakehealth.edu
2 Financial Disclosure I currently have or have had the following relevant financial relations to disclose: -Speaker s Bureau: Celgene, Ypsen Oncology -Honorarium/Fees Paid: Celgene, Ypsen Oncology Wake Forest Baptist Medical Center 2
3 Off Label Use Disclosure I do not intend to discuss an off label use of a product during this activity. Wake Forest Baptist Medical Center 3
4 Wake Forest Baptist Medical Center Pancreatic Cancer
5 Pancreatic Adenocarcinoma Pancreatic ductal adenocarcinoma (PDAC) is now the third leading case of cancer deaths in the USA Although there have been recent advancements in systemic therapy for metastatic disease with the FOLFIRINOX and gemcitabine/nabpaclitaxel regimens, the survival rates for PDAC remain poor The most established risk factor pancreas cancer is cigarette smoking and is associated with about 25% of the cases. A minority of PDAC patients (less than 20%) are diagnosed at an early stage where surgery may be beneficial Ø In these patients, accurate staging is required to define potential resectability In patients with resectable PDAC, the current standard of care is upfront surgery followed by adjuvant therapy 1. American Cancer Society Cancer Facts and Figures 2. Fuchs CS et al. Arch Intern Med Oct;156(19):
6 Adjuvant Therapy Wake Forest Baptist Medical Center 6
7 CONKO-001 Resected pancreatic cancer 368 patients Stratification: R; T; N Gemcitabine for six months Observation for six months Follow up every eight weeks Oettle H et al. JAMA. 2007;297(3):
8 CONKO-001 Survival Results Median DFS13.4 vs. 6.7 months Median OS 22.8 vs months Oettle H et al. JAMA. 2007;297(3): Abbreviations: DFS, disease free survival; OS, overall survival
9 ESPAC-3, N=1,088: Gemcitabine Not Better Than 5-FU/FA Median S(t)= 23.0 months (95%CI:21.1, 25.0) Median S(t)= 23.6 months (95%CI:21.4, 26.4) c 2 LR=0.74, p=0.39, HR GEM VS. 5FU/FA =0.94 (95%CI: 0.81, 1.08) Months from Resection No. at Risk 5FU/FA GEM Neoptolemos J, et al. J Clin Oncol 34, 2016 (suppl; abstr LBA4006)
10 ESPAC-4 Trial Stratified log-rank test with 5% 2-sided α, for a 10% difference in 2 year survival, 90% power = 480 events = 722 patients, 361 arm 722 patients Pancreatic ductal adenocarcinoma curative resection < 12 weeks RANDOMIZATION at Liverpool Cancer Trials Unit GEMCITABINE 1000mg/m 2 Days 1, 8, & 15 for 6 cycles GEMCITABINE 1000mg/m2 Days 1, 8, & 15 for 6 cycles CAPECITABINE 1660mg/m2 /day d i.e. 24 weeks Neoptolemos J. Lancet 389; 1011, monthly follow up from randomization to death
11 ESPAC-4: Overall Survival Neoptolemos J. Lancet 389; 1011, 2017
12 ESPAC-4: Reported Toxicity Number of patients in Safety Set with at least one NCI CTC v4 grade 3/4 event CTC 3/4 event * Exploratory analysis: Fisher s exact test GEM Number of patients (% of 366) P-value* GEMCAP Number of patients (% of 359) Anaemia 14 (4%) (2%) Diarrhoea 6 (2%) (5%) Fatigue 19 (5%) (6%) Fever 6 (2%) (2%) Infection and infestations, Other 24 (7%) (3%) Lymphocytes 11 (3%) (3%) Neutrophils 89 (24%) < (38%) Hand-Foot syndrome 0 (0%) < (7%) Platelets 7 (2%) (2%) Thromboembolic event 9 (2%) (2%) WBC 28 (8%) (10%) Neoptolemos J. Lancet 389; 1011, 2017
13 ESPAC Trials: Summary of Results Trial ESPAC-1 ESPAC-3 ESPAC-4 Treatment Number of patients (N=2,092) 5-Year OS (95% CI) 5FU/FA ( ) % No chemotherapy ( ) % Chemoradiotherapy (5FU/Rad) ( ) % GEM ( ) % 5FU/FA ( ) % GEM ( ) % GEMCAP ( ) % Stratified Log-Rank x 2 p-value * * *Stratification factor: resection margin status; stratification factors: resection margin status and country Neoptolemos J. Lancet 389; 1011, 2017
14 Slide 3 Presented By Thierry Conroy at 2018 ASCO Annual Meeting
15 Key Inclusion Criteria Presented By Thierry Conroy at 2018 ASCO Annual Meeting
16 Safety: main nonhematologic AEs Presented By Thierry Conroy at 2018 ASCO Annual Meeting
17 Disease-Free Survival Presented By Thierry Conroy at 2018 ASCO Annual Meeting
18 Slide 21 Presented By Thierry Conroy at 2018 ASCO Annual Meeting
19 Conclusions Presented By Thierry Conroy at 2018 ASCO Annual Meeting
20 PANCREAS CANCER NEO-ADJUVANT THERAPY PERIOPERATIVE THERAPY
21 Trial design Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting
22 Results Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting
23 Overall survival (ITT) Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting
24 Disease free survival Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting
25 Metastases and local recurrence (ITT) Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting
26 Conclusion Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting
27 We Have Made Progress in the 1 st -Line Metastatic Setting Trial 1 Date Patients (n) Treatment Burris et al NCIC PRODIGE Ueno, et al MPACT (unresectable, LA or metastatic pancreatic cancer) 569 (unresectable, LA or metastatic pancreatic cancer) 342 (metastatic) 834 (LA, or metastatic pancreatic cancer) 861 (metastatic) 5-FU vs. gemcitabine gemcitabine vs. gemcitabine + erlotinib gemcitabine vs. FOLFIRINOX gemcitabine vs. S-1 vs. gemcitabine + S-1 gemcitabine vs. gemcitabine + nab-paclitaxel Median survival (mo) * P value Log-Rank Test (HR = 0.82 [95% CI, ]) <0.001 (HR = 0.57 [95% CI, ]) gemcitabine vs. S-1: <0.001 (non-inferiority; HR = 0.96 [97.5% CI, ]) gemcitabine vs. gemcitabine + S-1: 0.15 (superiority; HR = 0.88 [97.5% CI, ]) <0.001 (HR = 0.72 [95% CI, ]) 1. Ryan DP, et al. N Engl J Med 2014;371:1039; 2. Burris HA, et al. J Clin Oncol 1997;15:2403; 3. Moore MJ, et al. J Clin Oncol 2007;25:1960; 4.Conroy T, et al. N Engl J Med 2011;364:1817; 5. Ueno H, et al. J Clin Oncol 2013;31:1640; 6. Von Hoff DD, et al. N Engl J Med 2013;369:1691.
28 1 st -line treatment of MPC Nab-paclitaxel + gemcitabine or FOLFIRINOX? Nab-P/Gem (n=431) FOLFIRINOX (n=171) Sites Global France Age >75? Yes? PS Efficacy RR,% PFS, months OS (updated), months 1 year, % Safety, G 3 events, % Febrile neutropenia Growth factors Fatigue Vomiting Diarrhoea Neuropathy b Von Hoff et al. N Engl J Med 2013;369: ; 2. Goldstein et al. JNCI 2015; Jan 31;107. pii: dju413. doi: /jnci/dju41; 3. Conroy et al. NEJM 2011;364:
29 Design of PRODIGE 35 PANOPTIMOX study Wake Forest Baptist Medical Center Presented By Laetitia Dahan at 2018 ASCO Annual Meeting
30 PRIMARY ENDPOINT (mitt): <br />6 months Progression Free Survival rate Wake Forest Baptist Medical Center Presented By Laetitia Dahan at 2018 ASCO Annual Meeting
31 PROGRESSION FREE SURVIVAL (PFS) Wake Forest Baptist Medical Center Presented By Laetitia Dahan at 2018 ASCO Annual Meeting
32 OVERALL SURVIVAL (OS) Wake Forest Baptist Medical Center Presented By Laetitia Dahan at 2018 ASCO Annual Meeting
33 CONCLUSIONS Wake Forest Baptist Medical Center Presented By Laetitia Dahan at 2018 ASCO Annual Meeting
34 Key Eligibility (N=417) NAPOLI-1: PHASE 3 STUDY OVERVIEW 1,2 Confirmed metastatic pancreatic cancer Progression of locally advanced or metastatic disease Prior gemcitabinebased therapy Normal bilirubin Albumin 3.0 g/dl KPS 70 R ONIVYDE (irinotecan liposome injection) 100 mg/m 2, q3w 5-FU/LV 2000/200 mg/m 2 weekly x 4, q6w Initial design n=33 n=30 ONIVYDE + 5-FU/LV 70 mg/m /400 mg/m 2, q2w After amendment n=118 n=119 Stratification factors: Albumin (<4.0 g/dl vs 4.0 g/dl); KPS (70 and 80 vs 90); and ethnicity (Caucasian vs East Asian vs others) Treatment continued until disease progression or unacceptable toxicity Total n=151 n=149 n=117 n=117 Please see Important Safety Information, including Boxed WARNING, within this presentation and accompanying full Prescribing Information for ONIVYDE. KPS=Karnofsky performance status. References: 1. Wang-Gillam A, et al. Lancet. 2016;387: Wake Forest Baptist Medical Center 22
35 EXTENDED OVERALL SURVIVAL 1 ONIVYDE (IRINOTECAN LIPOSOME INJECTION) + 5-FU/LV DEMONSTRATED A STATISTICALLY SIGNIFICANT INCREASE IN MEDIAN OS VS 5-FU/LV Probabilityof Survival # at risk: Time From Randomization (Months) ONIVYDE FU/LV 5-FU/LV Median OS HR=0.68 [95% CI: 0.50, 0.93]; log-rank p=0.014 ONIVYDE + 5-FU/LV (95% CI: 4.8, 8.5) 5-FU/LV (95% CI: 3.3, 5.3) 6.1 MONTHS 4.2 MONTHS ONIVYDE is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas. There was no improvement in OS for ONIVYDE vs 5-FU/LV (HR=1.00; p=0.97 [two-sided log-rank]) Please see Important Safety Information, including Boxed WARNING, within this presentation and accompanying full Prescribing Information for ONIVYDE. Reference: Wake 1. ONIVYDE Forest Baptist [packaemedical insert]. Ipsen Center Biopharmaceuticals, Inc.;
36 Current Approach in Treatment Sequencing for mpca 3 rd line 2 nd line 1 st line Gemcitabine-Nabpaclitaxel (PS 0-1): Nal-Irinotecan+ 5FU (PS 2): 5FU, Capecitabine or BSC (PS 0-1): Platinum-based regimen if no prior exposure FOLFIRINOX (PS 0-1): Gemcitabine/nabpaclitaxel? (PS 2): Gemcitabine or BSC?? BSC, best supportive care; PS, performance status.
37 HALO-202 Randomized Phase 2 Study of PEGPH20 Plus nab-paclitaxel/ Gemcitabine (AG) vs. AG in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma All Patients ( Primary Analysis) High HA ( Exploratory Analysis) Combo PAG AG PAG AG N pts mpfs (mos) HR p=0.045 HR 0.51 p=0.048 mos (mos) HR p HR 0.96 p=0.88 RR (%) Main AEs PAG: Fatigue, Hematologic and thromboembolic events AG : Fatigue and Hematologic Hingorani SL. Abs ASCO 2017, Wake Forest Baptist Medical Center
38 Which Subsets of Patients Might Benefit From Specific Therapies? MSI-high/mismatch repair-deficient (dmmr) 5/6 patients with dmmr pancreatic cancers showed objective response by RECIST to pembrolizumab BRCA- or PALB2- mutation carriers Rucaparib: 3/19 (16%) with objective response Olaparib: 5/23 pts (22%) with objective response Veliparib: 0/16 pts with objective response Wake Forest Baptist Medical Center 1. Kaufman, et al. J Clin Oncol. 2015;33: Lowery, et al. ASCO Abstract Le D, et al. ASCO Abstract 195.
39 Slide 64 Presented By Dung Le at 2017 ASCO Annual Meeting
40 Conclusions 1 FOLFIRINOX is an adjuvant standard in pancreas cancer. PS, organ function, recovery from surgery Perioperative chemotherapy and preoperative hypofractionated radiotherapy is an emerging option for resectable and borderline resectable pancreas cancer Should we incorporate hypofractionated XRT to FOLFIRINOX? Alliance Trial Wake Forest Baptist Medical Center 41
41 Conclusions 2 Participation in clinical trials is paramount and should be the first line of choice. Folfirinox is an option in good organ function and PS 0-1. Gem/Nab is an option for patients with PS 0-2. Liposomal Irinotecan + 5- FU is the second-line option based on phase III data. Level 1 by NCCN guidelines. The sequence of treatment is dictated by patient characteristics and physician choice rather than efficacy.
42 Conclusions 3 In metastatic pancreas cancer FOLFIRINOX followed by maintenance 5FU is an option. Activity in MSI-High tumors is stablished Targeted Therapy and immunotherapy combo are emerging. Biomarkers to predict benefit from therapy are desperately needed. Wake Forest Baptist Medical Center
43 Thanks For The Attention!!!
Overview. What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013
What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013 Overview Staging and Workup Resectable Disease Surgery Adjuvant therapy Locally
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationPancreatic Ductal Adenocarcinoma. Razvan Popescu Tumor Center Aarau Switzerland
Pancreatic Ductal Adenocarcinoma Razvan Popescu Tumor Center Aarau Switzerland Median Survival of Patients With Pancreatic Cancer Localized/ Resectable 15-24 months 10% Locally Advanced 6-15 months 30%
More informationPancreatic Adenocarcinoma
Pancreatic Adenocarcinoma AProf Lara Lipton 28 April 2018 Percentage alive 5 years after diagnosis for men and women Epidemiology 6% of cancer related deaths worldwide 4 th highest cause of cancer death
More informationReference No: Author(s) 12/05/16. Approval date: committee. June Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Adenocarcinoma Dr Colin Purcell, Consultant Medical Oncologist & on behalf of the GI Oncologists Group, Cancer
More informationWhat Is The Optimal Adjuvant Therapy in Pancreatic Adenoca: Intensified Chemotherapy March 28 th, 2015
What Is The Optimal Adjuvant Therapy in Pancreatic Adenoca: Intensified Chemotherapy March 28 th, 2015 Eileen M. O Reilly, M.D. Associate Director David M. Rubenstein Center Pancreatic Cancer Research
More informationConcept to Practice: New Advances in the Treatment of GI Cancers
Concept to Practice: New Advances in the Treatment of GI Cancers 2016 Community Oncology Alliance Conference Orlando, FL Thomas George, MD, FACP Director, GI Oncology Program Director, Experimental Therapeutics
More informationDr Roopinder Gillmore July 2017
Dr Roopinder Gillmore July 2017 Resectable Borderline / locally advanced Metastatic 15-20% 15-20% 60-70% 22-28 months 9-15 months 6-12 months Does the patient have resectable disease?? Definitely not
More informationPancreatic Cancer: Light at the End of the (Very Long) Tunnel
Pancreatic Cancer: Light at the End of the (Very Long) Tunnel Daniel Renouf, MD, MPH, FRCPC Medical Oncologist, BC Cancer Agency University of British Columbia Objectives 1. Discuss recent updates in systemic
More informationPancreas Cancer Update Systemic Treatments
Pancreas Cancer Update Systemic Treatments Carlos R Becerra. Baylor University Medical Center Stage Distribution for Pancreas Cancer in the US (24-21) 1 9 8 7 Axis Title 6 5 4 53 3 28 2 1 9 11 Localized
More informationAdjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD
Adjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD Efficacy Parameters in adjuvant monochemotherapy Randomized studies in resectable PDAC Regimen DFS HR (p) OS HR (p) 5-yr-OS
More informationTough to treat tumors in elderly. how far can we go? Jean-Luc Raoul Institut Paoli-Calmettes Marseille France
Tough to treat tumors in elderly Pancreatic cancer: how far can we go? Jean-Luc Raoul Institut Paoli-Calmettes Marseille France Top 5 causes of cancer death / age Cancer Statistics in the USA 2008, CA
More informationLA CHEMIOTERAPIA DI I LINEA
DECIDERE LA CHEMIOTERAPIA ADIUVANTE E DELLA MALATTIA METASTATICA LA CHEMIOTERAPIA DI I LINEA Michele Reni Department of Medical Oncology IRCCS Ospedale San Raffaele Milan, Italy 1930 1940 1950 1960 1970
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationQuimioteràpia per l'adenocarcinoma de pàncrees. Com són de bons els resultats? Que esperem en un futur pròxim?
Quimioteràpia per l'adenocarcinoma de pàncrees. Com són de bons els resultats? Que esperem en un futur pròxim? Carles Pericay (Oncologia. Hospital Parc Taulí) Projecting Cancer Deaths to 2030 Lung Rahib
More informationBest Practices and Promising Agents in Pancreatic Cancer. This program is supported by educational grants from Celgene Corporation and Incyte.
Best Practices and Promising Agents in Pancreatic Cancer This program is supported by educational grants from Celgene Corporation and Incyte. About These Slides Users are encouraged to use these slides
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationCáncer de Páncreas: Optimización del tratamiento sistémico
Cáncer de Páncreas: Optimización del tratamiento sistémico Alfredo Carrato Hospital Universitario Ramón y Cajal, Madrid 16 de Mayo de 2015 Pancreatic cancer screening There is a latency period of about
More informationAdjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009
HIGHLIGHT ARTICLE - Slide Show Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 Muhammad Wasif Saif
More informationPancreatic Cancer: Medical Therapeutic Approaches
Pancreatic Cancer: Medical Therapeutic Approaches Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat Pancreatic cancer: Why so difficult
More informationPancreatic Cancer. Maribel Tirado Gomez, MD Hematology and Medical Oncology
Pancreatic Cancer Maribel Tirado Gomez, MD Hematology and Medical Oncology Disclosures I have no actual or potential financial or commercial conflict of interest in relation to this presentation. Consulting
More informationOpciones terapéuticas de 1ª línea de cáncer de páncreas metastásico. Fernando Rivera Herrero Hospital Universitario Marqués de Valdecilla, Santander
Opciones terapéuticas de 1ª línea de cáncer de páncreas metastásico Fernando Rivera Herrero Hospital Universitario Marqués de Valdecilla, Santander Finantial disclosure Consultor: CELGENE Research fundings:
More informationUpdate on Pancreatic Cancer
Update on Pancreatic Cancer Farshid Dayyani, MD, PhD Associate Clinical Professor, Department of Medicine, UC Irvine School of Medicine February 2 nd, 2018 Overview Current Systemic Treatments Adjuvant
More informationPancreatic cancer from the past to the future
Pancreatic cancer from the past to the future Darren Sigal, MD Scripps Clinic Pancreas and Bile Duct Cancer Group Division of Hematology/Oncology Scripps Clinic Pancreas and Bile Duct Cancer Group 1 Objectives
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationThe 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract
The 2010 Gastrointestinal Cancers Symposium : Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract Abstract #131: Phase I study of MK 0646 (dalotuzumab), a humanized monoclonal antibody against
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationRecent Advances in Gastrointestinal Cancers
Recent Advances in Gastrointestinal Cancers Ursina R. Teitelbaum, MD Section of Hematology/Oncology Abramson Cancer Center PENN 2016 Updates in Oncology June 23, 2016 none Disclosures ASCO 2016 Highlights:
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationPRODUCT INFORMATION 1 ABOUT THIS GUIDE DOSAGE FORM AND STRENGTH STORAGE AND HANDLING
DOSING GUIDE INDICATION ONIVYDE (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of
More informationExpert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides
Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer Reference Slides Overview BRCA Mutations and Breast Cancer Patients with BRCA mutations have an estimated 55% to 65% cumulative
More informationFuture Perspectives in mpca. Michel Ducreux, MD, PhD Gustave Roussy Villejuif, France
Future Perspectives in mpca Michel Ducreux, MD, PhD Gustave Roussy Villejuif, France Number of Novel Therapies and Targets in Pancreatic Cancer Are Expanding Garrido-Laguna I, et al. Nat Rev Clin Oncol.
More informationPancreatic Ductal Adenocarcinoma. Razvan Popescu Tumor Center Aarau Switzerland
Pancreatic Ductal Adenocarcinoma Razvan Popescu Tumor Center Aarau Switzerland Teaching aims Discuss role of palliative care in PDAC Metastatic or locally advanced irresectable disease First line Therapies
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationPhase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma
Original Article Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma Werner Scheithauer 1, Gabriela Kornek 1, Gerald Prager 1, Nadja Stranzl 1, Friedrich
More informationASCO Poster Review PANCREATIC CANCER
ASCO Poster Review PANCREATIC CANCER Dr.ssa Michela Squadroni U.O. Oncologia Humanitas Gavazzeni Bergamo TOPICAL ISSUES Gemcitabine/Nab-paclitaxel and FOLFIRINOX comparison Neoadjuvant and perioperative
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationTumores Bilio-Pancreaticos Carlos Gomez-Martin Hospital Universitario 12 de Octubre. Madrid
Tumores Bilio-Pancreaticos Carlos Gomez-Martin Hospital Universitario 12 de Octubre. Madrid Pancreatic Cancer Pancreatic Cancer Pancreatic Cancer Entity Resectable Borderline Resectable Locally advanced
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationTrends in Neoadjuvant Approaches in Pancreatic Cancer
1070 Trends in Neoadjuvant Approaches in Pancreatic Cancer Lingling Du, MD, and Andrea Wang-Gillam, MD, PhD Abstract Pancreatic cancer (PDAC) is an aggressive tumor type associated with development of
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT
ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE
More information13TH ANNUAL NEW ORLEANS SUMMER CANCER MEETING
13TH ANNUAL NEW ORLEANS SUMMER CANCER MEETING First-line FOLFOX plus panitumumab (pan) followed by 5-FU/LV plus pan or single-agent pan as maintenance therapy in patients with RAS wild-type metastatic
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Nab-Paclitaxel (Abraxane) for Pancreatic Cancer September 23, 2014
pan-canadian Oncology Drug Review Final Clinical Guidance Report Nab-Paclitaxel (Abraxane) for Pancreatic Cancer September 23, 2014 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationSystemic management of pancreatic cancer: Supportive care
Systemic management of pancreatic cancer: Supportive care Snežana Bošnjak Institute for Oncology and Radiology of Serbia Dept. Supportive Oncology & Palliative Care Serbia, Belgrade Integrative Oncology
More informationPancreatic Cancer. BIOLOGY: Not well defined (genetic and enviromental factors) CLINICAL PRESENTATION: Abd pain, jaundice, weight loss.
EloreMed Editor: Le Wang, MD, PhD Date of Update: 2/6/2018 UpToDate: Liposomal irinotecan (Onivyde) plus FU/LV is now approved for gemcitabine-refractory metastatic pancreatic cancer and recommended by
More informationADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000
More informationDALLA CAPECITABINA AL TAS 102
DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationAvances recientes en el cáncer de páncreas avanzado. P. García Alfonso Jefe de Sección Oncología Médica HGU Gregorio Marañón de Madrid
Avances recientes en el cáncer de páncreas avanzado P. García Alfonso Jefe de Sección Oncología Médica HGU Gregorio Marañón de Madrid Pancreatic Cancer: Incidence & Mortality Siegel R, et al. CA Cancer
More informationSystemic Cytotoxic Therapy in advanced HCC
Systemic Cytotoxic Therapy in advanced HCC Yeul Hong Kim Korea University Anam Hospital Cancer Center Hepatocellular Carcinoma : Overview Epidemiology Current Guideline : advanced HCC Cytotoxic Chemotherapy
More informationIncorporating biologics in the management of older patients with metastatic colorectal cancer
Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationConflicts of Interest GI Malignancies: An Update on Current Treatment Options
Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationSidra Anwar 1, Wei Tan 2, Jinhee Yu 3, Alan Hutson 2, Milind Javle 4, Renuka Iyer 5. Introduction
Original Article Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicenter phase 2 trial Sidra Anwar
More informationTrabectedin in ASTS. Le Cesne A, et al. J Clin Oncol. 2018;36(suppl): Abstract
Results of a Prospective Randomized Phase III T-SAR Trial Comparing Trabectedin vs Best Supportive Care (BSC) in Patients With Pretreated Advanced Soft Tissue Sarcoma (ASTS) Abstract 11508 Le Cesne A,
More informationL oncologo Alberto Zaniboni
COME TRATTARE LA NEOPLASIA LOCALMENTE AVANZATA BORDERLINE PER RESECABILITA L oncologo Alberto Zaniboni Oncologia Medica Fondazione Poliambulanza - Brescia Pancreatic cancer deaths in 2030 Pancreatic cancer
More informationCetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS)
Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) C Bokemeyer, E Staroslawska, A Makhson, I Bondarenko, JT Hartmann,
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationpan-canadian Oncology Drug Review Final Economic Guidance Report Irinotecan liposome (Onivyde) for Metastatic Pancreatic Cancer January 5, 2018
pan-canadian Oncology Drug Review Final Economic Guidance Report Irinotecan liposome (Onivyde) for Metastatic Pancreatic Cancer January 5, 2018 DISCLAIMER Not a Substitute for Professional Advice This
More informationTreatment Approaches for Pancreatic Cancer: Hope on the Horizon Disclosures
Treatment Approaches for Pancreatic Cancer: Hope on the Horizon Michael Pishvaian, MD, PhD Director, Phase I Program Assistant Professor Lombardi Comprehensive Cancer Center Georgetown University Disclosures
More informationSystemic Treatments for Esophagogastric and Pancreas Cancer in the Adjuvant and Metastatic Settings
Systemic Treatments for Esophagogastric and Pancreas Cancer in the Adjuvant and Metastatic Settings Peter C. Enzinger, MD Dana-Farber Cancer Institute & Harvard Medical School 2017 Master Class Course
More informationintent treatment be in the elderly?
Gastric cancer: How strong can curative intent treatment be in the elderly? Caio Max S. Rocha Lima, M.D. Professor of Medicine University of Miami & Sylvester Cancer Center Gastric cancer: epidemiology
More informationΚίκα Πλοιαρχοπούλου. Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών
Κίκα Πλοιαρχοπούλου Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών Time (months) Survival outcomes in mcrc have progressively improved over the past two decades Treatment options for many patients Multidisciplinary
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationColon cancer: Highlights. Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano
Colon cancer: Highlights Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano Agenda 1) Metastatic colorectal cancer First-line treatment molecularly unselected: FOLFOXIRI-bev (CHARTA trial) Later-line
More informationPancreatic Cancer Where are we?
Pancreatic Cancer Treatment Approaches & Options Pancreatic Cancer Action Network OUMC 9/22/2016 Russell G. Postier, MD Pancreatic Cancer Where are we? Estimated 2016 data 3% of cancer cases 7% of cancer
More informationPancreatic Cancer and Radiation Therapy
Pancreatic Cancer and Radiation Therapy Why? Is there a role for local therapy with radiation in a disease with such a high rate of distant metastases? When? Resectable Disease Is there a role for post-op
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D.
ASCO 2017 updates in Colorectal and Gastric Cancers May Cho, M.D. Relevant financial relationships in the past twelve months by presenter or spouse/partner: None The speaker will directly disclosure the
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More information